CNS Pharma Q1 net loss $4.9M; Berubicin interim analysis on track for Q3 2023

CNS Pharmaceuticals, Inc.

2023-Q1 EPS reported -$2.59

Net loss $4.9M vs $3.2M YoY; R&D expense $3.6M (+$1.7M) driven by CRO costs for Berubicin trial.
Cash $5.1M at Mar 31; subsequent ATM raised ~$2.0M (avg $3.08/share) and ~$0.7M from warrant exercises.
Enrollment >100 patients in potentially pivotal Berubicin GBM trial; 45 of 60 sites open across US and Europe.
Interim analysis results expected Q3 2023; topline data after enrollment complete.
Appointed Dr. Bettina Cockroft and Faith Charles to Board, strengthening biopharma and governance expertise.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CNS Pharmaceuticals, Inc. reported the quarter ended March 31, 2023 results: net income approximately $4.9 million.

Period: the quarter ended March 31, 2023
Net income: approximately $4.9 million
Result: reported results

Exact text from the filing

The net loss for the three months ended March 31, 2023 was approximately $4.9 million compared to approximately $3.2 million for the comparable period in 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-003312

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.